Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Gene Variant Descriptions||FGFR2 rearrangement indicates an unspecified rearrangement of the FGFR2 gene.|
|Associated Drug Resistance|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|FGFR2 rearrange||cholangiocarcinoma||predicted - sensitive||Futibatinib||Phase I||Actionable||In a Phase I trial, TAS-120 treatment resulted in partial response in 2 patients with cholangiocarcinoma harboring FGFR2 rearrangements (Annals of Oncology, Volume 29, Issue suppl_5).||detail...|
|FGFR2 rearrange||intrahepatic cholangiocarcinoma||sensitive||Pemigatinib||Guideline||Actionable||Pemazyre (pemigatinib) is included in guidelines as subsequent-line therapy for intrahepatic cholangiocarcinoma patients with disease progression harboring an FGFR2 fusion or rearrangement (NCCN.org).||detail...|
|FGFR2 rearrange||cholangiocarcinoma||sensitive||Pemigatinib||FDA approved - Has Companion Diagnostic||Actionable||In a Phase II (FIGHT-202) trial, Pemazyre (pemigatinib) treatment resulted in an objective response in 35.5% (38/107, 3 complete response, 35 partial response) of patients with advanced cholangiocarcinoma harboring FGFR2 fusions or rearrangements, with a disease control rate of 82% (88/107), median time-to-response of 2.7 months, and a median progression-free survival of 6.9 months (PMID: 32203698; NCT02924376).||detail... 32203698 detail...|
|FGFR2 amp FGFR2 rearrange||cholangiocarcinoma||predicted - sensitive||Futibatinib||Phase I||Actionable||In a Phase I trial, TAS-120 treatment resulted in partial response in a patient with cholangiocarcinoma harboring FGFR2 rearrangement and FGFR2 amplification (Annals of Oncology, Volume 29, Issue suppl_5).||detail...|